Precision medicine study for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at your tumor sample to learn more about your multiple myeloma and find the best treatment for you. It does not give you a new drug, but uses your standard biopsy to help guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your multiple myeloma has come back (relapsed).
- You are already scheduled for a bone marrow or tumor biopsy as part of your regular care.
- Your doctor agrees to the study and you are willing to take part.
- You are not in another clinical trial that uses strong drugs against multiple myeloma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This trial tests an experimental drug called JNJ-79635322 for people with multiple myeloma that has come back or hasn't responded to at least three previous treatments, including a PI, an IMiD, and a CD38-targeted antibody. The goal is to see if this new drug can help control the disease.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.